Onesource Specl Pharma L
NSE: ONESOURCE · Pharmaceuticals · sector
₹1,397.30NSE close 2026-10-26
Key numbers
Market cap₹16,019 cr
Price₹1,397.30
52w high / low₹1,925 / ₹1,057
P/E–Sector median 27.9x
P/B2.8xSector median 2.9x
Book value₹508.7
Dividend yield–Sector median 0.48%
ROE-0.8%Sector median 11.7%
ROCE0.8%Sector median 12.3%
OPM21.2%Sector median 14.0%
Debt / equity0.22xSector median 0.16x
EV/EBITDA52.5xSector median 18.6x
Interest cover0.5x
Current ratio0.99x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹103 cr vs borrowings ₹1,276 cr (FY26): borrowings are higher by ₹1,173 cr.
- Operating profit covered interest 0.5x in the last 12 months.
- 38.79% of the promoters' shares are pledged (11.8% of all shares).
- Promoter holding rose by 0.70 percentage points in a year, to 30.47% (2026-09-30).
- Net loss in 4 of the last 8 quarters.
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- No dividend in the last 2 financial years.
- Price ₹1,397.30 on 2026-10-26: -27.4% from the 52-week high, +32.2% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹2,170.20 · low ₹1,119.90
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| EBITDA | 0 | 43 | 183 | 86 | 106 | 10 | 92 | 119 |
| OPM % | 0.2% | 10.9% | 42.8% | 26.2% | 28.3% | 3.5% | 21.5% | 26.5% |
| Other income | 1 | 5 | 3 | 5 | 3 | 5 | 2 | 4 |
| Net profit | -39 | -69 | 98 | -0 | 10 | -89 | 5 | 25 |
| EPS (₹) | -18.82 | -6.31 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 | 2.18 |
| Revenue YoY | +452.8% | -26.0% | +0.5% | +37.2% | ||||
| Profit YoY | – | – | -95.3% | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY25 | FY26 | TTM |
|---|---|---|---|
| Revenue | 1,445 | 1,422 | 1,543 |
| EBITDA | 356 | 294 | 328 |
| Net profit | -18 | -74 | -49 |
| EPS (₹) | -1.63 | -6.44 | -4.24 |
| Revenue growth | -1.6% | +27.1% | |
| Profit growth | – | – | |
| Dividend / share (₹) | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | +27.2% |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | -26.6% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 5,881 | 5,831 |
| Borrowings | 772 | 1,276 |
| Cash & equivalents | 310 | 103 |
| Total assets | 7,550 | 8,210 |
| Fixed assets | 897 | 926 |
| Capital work in progress | 60 | 314 |
| Investments | 7 | 10 |
| Receivables | 417 | 690 |
| Inventory | 158 | 439 |
| Payables | 176 | 375 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -22 | 9 |
| Cash from investing | -201 | -495 |
| Cash from financing | 1,987 | 359 |
| Capex | 0 | 569 |
| Free cash flow | -22 | -561 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -0.3% | -1.3% |
| ROCE % | 1.5% | 0.4% |
| Debtor days | 105 | 177 |
| Inventory days | 133 | 360 |
| Payable days | 147 | 307 |
| Cash conversion cycle (days) | 91 | 230 |
| Working capital days | -7 | -4 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 30.47% |
| FIIs | 19.46% |
| DIIs | 24.21% |
| of which Mutual funds | 13.76% |
| of which Insurance | 4.12% |
| Government | 0.00% |
| Public (non-institutions) | 25.86% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 37.77% | 34.25% | 29.79% | 29.77% | 29.93% | 30.48% | 30.48% | 30.47% |
| Promoter group | % |
|---|---|
| Tenshi Pharmaceuticals Private Limited | 18.39% |
| Karuna Business Solutions LLP | 7.06% |
| Pronomz Ventures LLP | 2.41% |
| Arco LAB Private Limited | 1.60% |
| Arun Kumar Pillai | 0.85% |
| Padmakumar Karunakaran Pillai | 0.04% |
| Vineetha Mohanakumar Pillai | 0.04% |
| Aditya Arun Kumar | 0.03% |
| Rajitha Gopalakrishnan | 0.03% |
| Sajitha Pillai | 0.03% |
| Hemalatha Pillai | 0.00% |
| Public holders above 1% | % |
|---|---|
| Motilal Oswal Mutual Fund | 7.02% |
| Authum Investment and Infrastructure Limited | 4.95% |
| SBI Life Insurance Co. Ltd | 2.89% |
| Route ONE Offshore Master Fund L.P. | 2.32% |
| Route ONE Fund I, L.P. | 2.07% |
| Think Investments PCC | 1.79% |
| Fidelity Securities Fund: Fidelity Blue Chip Growth Fund | 1.76% |
| 360 ONE Special Opportunities Fund - Series 12 | 1.62% |
| Amansa Holdings Private Limited | 1.58% |
| Axis Mutual Fund | 1.38% |
| 360 ONE Mutual Fund | 1.24% |
| Mirae Asset | 1.13% |
| Timf Holdings | 1.05% |
79,770 shareholders. Pledged: 38.79% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ONESOURCE | ₹16,019 cr | – | 2.8x | -0.8% | 0.8% | 21.2% | – | – |
Documents
- Annual report FY26
- Annual report FY25
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Manufacturing: Manufacture of Pharmaceutical products
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ONESOURCE |
| BSE code | 544292 |
| ISIN | INE013P01021 |
| Face value | ₹1.0 |
| Incorporated | 2007-06-12 |
| Website | https://www.onesourcecdmo.com |
| Plants (India / abroad) | 4 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.